“The drug offers so modest a benefit that doctors and patients might not perceive any effect whatsoever.”
Fabricated data sat at the core of the amyloid hypothesis for years. Leqembi strips amyloid, and patients decline only slightly slower than on placebo. Researchers chasing other theories were starved of money and bullied. Billions went to the wrong idea.